- Home
- INMB vs IMA Comparison
INMB vs IMA Comparison
Compare INMB & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | IMA |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 66.3M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INMB | IMA |
|---|---|---|
| Price | $2.17 | $5.63 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $5.40 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 354.0K | 9.9K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,000.00 | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $3.94 |
| 52 Week High | $2.58 | $15.27 |
Technical Indicators
Market Signals| Indicator | INMB | IMA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.94 |
| Support Level | N/A | $5.86 |
| Resistance Level | N/A | $6.13 |
| Average True Range (ATR) | 0.00 | 0.29 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 76.39 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.